Evidence map›Paper›PMID 36201127›Full record

ArticleBreast cancer research and treatment2022

Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis.

Jeanna Wallenta Law, Alicyn Campbell, Colin Weller, Colden Johanson, Ronda Broome, Elisabeth Piault, Monika Izano, Andrew Schrag, Mary Tran, Thomas D Brown and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Jeanna Wallenta LawSyapse, 303 2nd Street, North Tower, Suite 500, San Francisco, CA, 94107, USA. Jeanna.law@syapse.com.
Alicyn CampbellAstraZeneca, 1800 Concord Pike, Wilmington, DE, 19850, USA.
Colin WellerAstraZeneca, 1800 Concord Pike, Wilmington, DE, 19850, USA.
Colden JohansonSyapse, 303 2nd Street, North Tower, Suite 500, San Francisco, CA, 94107, USA.
Ronda BroomeSyapse, 303 2nd Street, North Tower, Suite 500, San Francisco, CA, 94107, USA.
Elisabeth PiaultAstraZeneca, 1800 Concord Pike, Wilmington, DE, 19850, USA.
Monika IzanoSyapse, 303 2nd Street, North Tower, Suite 500, San Francisco, CA, 94107, USA.ORCID http://orcid.org/0000-0003-1852-5342
Andrew SchragSyapse, 303 2nd Street, North Tower, Suite 500, San Francisco, CA, 94107, USA.
Mary TranSyapse, 303 2nd Street, North Tower, Suite 500, San Francisco, CA, 94107, USA.
Thomas D BrownSyapse, 303 2nd Street, North Tower, Suite 500, San Francisco, CA, 94107, USA.
Henry G KaplanSwedish Cancer Institute, 1221 Madison St, Seattle, WA, 98104, USA.
Tower Urology Medical Group · USAstraZeneca (United States) · USSwedish Medical Center · USSylvana Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUsing real-world data, interstitial lung disease (ILD) prevalence before and after HER2-directed therapy was estimated. Potential ILD risk factors in patients receiving HER2-directed therapy for metastatic breast cancer (mBC) were evaluated.

methodsAdults with HER2-directed therapy for mBC initiated between September 25, 1998, and February 22, 2020 were, included. ILD was defined broadly as one or more of 64 lung conditions. Patients were followed until incident ILD, death, last contact, or study end.

resultsIn total, 533 patients were identified with median age at mBC of 57, 51% had de novo mBC, 43% were ever smokers, 30% had lung metastases, 9% had thoracic radiation, 6% had chronic obstructive pulmonary disease, and 16% had prevalent ILD. ILD cumulative incidence at one year was 9% (95% CI 6%, 12%), with a median follow-up of 23 months. Smoking (HR 2.2, 95% CI 1.1, 4.8) and Black/African-American race (HR 3.4, 95% CI 1.6, 7.5) were significantly associated with ILD; HRs for preexisting lung conditions (HR 1.8, 95% CI 0.9, 3.8) and thoracic radiation (HR 2.3, 95% CI 0.8, 7.1) were not statistically significant. Prevalent ILD was associated with 13-fold greater occurrence of incident ILD. 85% of patients with prevalent or incident ILD were symptomatic.

conclusionsThis real-world population of patients with mBC had a high prevalence of ILD prior to HER2-directed therapy, reflecting the multifactorial causation of interstitial lung changes. The cumulative incidence of ILD in patients receiving HER2-directed therapy for mBC augments prior reports. Symptomatic presentation suggests an opportunity for early intervention.

Indexed as

Breast NeoplasmsLung Diseases, InterstitialAdultData AnalysisErb-b2 Receptor Tyrosine KinasesFemaleHumansRetrospective StudiesErb-b2 Receptor Tyrosine KinasesEpidemiologyHER2-directed therapyInterstitial lung diseaseMetastatic breast cancerReal-world

Identifiers

PMID36201127
PMCPMC9633512
OpenAlexW4302763103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.